After recently announcing that it was mulling a partnership with BioNTech, Pfizer have announced that it has officially signed a deal with BioNTech to co-develop a potential vaccine for the coronavirus using BioNTech’s mRNA-based drug development platform.
The drugmakers will start the collaboration immediately and have signed a letter of intent for the vaccine’s distribution outside China.
According to the companies, they will use research and development sites from both in the U.S. and Germany.
Earliest this week, BioNTech made a deal with Shanghai Fosun Pharmaceutical over its rights in China to its experimental coronavirus vaccine.
The companies will finalize financial terms, and details regarding development, manufacturing and potential commercialization of the vaccine later this month.
Read the Reuters report